scholarly journals A Long Term Survival Case of Gastric Cancer with Peritoneal Dissemination Responding to Intraperitoneal Paclitaxel Combined with S-1 Chemotherapy

2014 ◽  
Vol 39 (2) ◽  
pp. 199-203
Author(s):  
Noriko Matsumoto ◽  
Mitsuo Shimada ◽  
Nobuhiro Kurita ◽  
Hirohiko Sato ◽  
Takashi Iwata ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Dissemination ◽  
Term Survival ◽  
Long Term Survival ◽  
Survival Case

scholarly journals Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Tomoya Takami ◽  
Koji Yasuda ◽  
Nozomi Uozumi ◽  
Yutaka Musiake ◽  
Hiroshi Shintani ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Adverse Events ◽  
Peritoneal Dissemination ◽  
Multidisciplinary Treatment ◽  
Term Survival ◽  
Long Term Survival ◽  
Recurrent Gastric Cancer

Abstract Background Recent advances in cancer immunotherapy have been remarkable, with many reports on the clinical effects of immune checkpoint inhibitors. Nivolumab has been covered by the national health insurance in Japan as a third-line agent for advanced and recurrent gastric cancer since September 2017. The objective response rate for nivolumab for gastric cancer is 11.2%. However, patients’ quality of life during this treatment has not been examined. Here, we report a case in which multidisciplinary treatment, including with nivolumab, resulted in long-term survival and improved quality of life. Case presentation A 70-year-old Asian woman was referred for surgery for gastric cancer. Postoperative pathological examination revealed peritoneal dissemination, and the patient was diagnosed with stage IV gastric cancer. Therefore, she was treated with S-1 and cisplatin based on negative immunohistochemical staining of resected specimens for human epidermal growth factor receptor 2. However, owing to instability and adverse events, treatment was subsequently changed to S-1 monotherapy. Two years after changing to S-1 monotherapy, she developed recurrence of peritoneal dissemination and was treated with docetaxel. Radiation therapy was also used because the recurrent lesions were local. However, 6 months later, new peritoneal dissemination and lymph node metastasis were observed and nivolumab was started. Subsequent abdominal computed tomography revealed a marked reduction in the disseminated nodules and lymphadenopathy. After 54 cycles of nivolumab, the lesions had disappeared completely. The patient has not developed side effects, including immune-responsive adverse events, has improved quality of life, and is returning to work. She is currently taking nivolumab, and there is no evidence of recurrence approximately 3 years after starting nivolumab. Conclusions Nivolumab may have beneficial effects in some patients with advanced or recurrent gastric cancer. Although the prognosis for gastric cancer and peritoneal dissemination is poor, multidisciplinary treatment that includes nivolumab may lead to long-term survival.

scholarly journals A Long-term Survival Case of Gastric Cancer Treated by Continuous Low-dosage 5-fluorouracil and Cisplatin: A Case Report.

2002 ◽  
Vol 49 (3) ◽  
pp. 157-160 ◽  
Author(s):  
KEISHIRO AOYAGI ◽  
KIKUO KOUFUJI ◽  
SHOJIRO YANG ◽  
NAOTAKA MURAKAMI ◽  
MOTOSHI MIYAGI ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Case Report ◽  
Term Survival ◽  
Long Term Survival ◽  
Low Dosage ◽  
Survival Case

scholarly journals Long-Term Survival of Three Recurrences during a Postoperative Follow-up of over 10 Years of a Gastric Cancer with Peritoneal Dissemination

2014 ◽  
Vol 47 (7) ◽  
pp. 374-380 ◽  
Author(s):  
Akihiro Kondo ◽  
Nozomi Hashimoto ◽  
Ryusuke Takebayashi ◽  
Akito Moroguchi ◽  
Reijirou Yamada ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Dissemination ◽  
Term Survival ◽  
Long Term Survival

scholarly journals A long-term survival case of unresectable gastric cancer with multidisciplinary therapy including immunotherapy and abscopal effect

2020 ◽  
Vol 9 (4) ◽  
pp. 193-198 ◽  
Author(s):  
Yuta Kuhara ◽  
Motoki Ninomiya ◽  
Satoshi Hirahara ◽  
Hirofumi Doi ◽  
Shirakawa Kenji ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Abscopal Effect ◽  
Multidisciplinary Therapy ◽  
Term Survival ◽  
Long Term Survival ◽  
Unresectable Gastric Cancer ◽  
Survival Case

scholarly journals Long-Term Survival of Two Patients with Liver Metastases from Advanced Gastric Cancer Treated with Radiofrequency Ablation and Chemotherapy

2021 ◽  
pp. 67-72
Author(s):  
Sung Jin Oh
Keyword(s):  
Gastric Cancer ◽  
Radiofrequency Ablation ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Systemic Chemotherapy ◽  
Subtotal Gastrectomy ◽  
Hepatic Metastases ◽  
Term Survival ◽  
Long Term Survival

Liver metastasis from gastric cancer has a very poor prognosis. Herein, we present two cases of liver metastases (synchronous and metachronous) from advanced gastric cancer. In the first case, the patient underwent radical subtotal gastrectomy. Liver metastases occurred 6 months after surgery while the patient was receiving adjuvant chemotherapy, but two hepatic tumors were successfully removed by radiofrequency ablation (RFA). In the second case, liver metastases occurred 15 months after surgery for gastric cancer. The patient also received RFA for one hepatic tumor, and other suspicious metastatic tumors were treated with systemic chemotherapy. Although these case presentations are limited for the efficacy of RFA treatment with systemic chemotherapy for hepatic metastases from gastric cancer, our findings showed long-term survival (overall survival for 108 and 67 months, respectively) of the affected patients, without recurrence. Therefore, we suggest that RFA treatment with systemic chemotherapy could be an effective alternative treatment modality for hepatic metastases from gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document